1. Introduction {#s0005}
===============

Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 5% of all cancers worldwide. In India they account for one-quarter to one-third of male cancers and one-tenth of cancers in females. HNSCC is often associated with heavy tobacco and alcohol use. People who use both tobacco and alcohol are at greater risk for developing these cancers than people who use either tobacco or alcohol alone ([@bb0105], [@bb0030]). Polymorphisms in genes such as cytochrome P450s (CYPs) & glutathione-S-transferases (GSTs), involved in the metabolism and detoxification of alcohol and constituents of tobacco are shown to influence an individual\'s susceptibility to cancer ([@bb0015], [@bb0075]). Studies including meta- and pooled analysis have shown that polymorphisms in phase I (*CYP1A1*, *CYP2E1*) & phase II (*GST*) enzymes are associated with tobacco induced HNSCC ([@bb0085], [@bb0190], [@bb0255]).

*CYP2C9* is one of the major drugs metabolizing CYP in human liver and contributes to the metabolism of a number of clinically important drugs such as anticoagulants and antihypertensives ([@bb0245]). *CYP2C9* is also known to be involved in the metabolism of some of the anti-neoplastic drugs such as cyclophosphamide, etoposide, tamoxifen and ifosfamide ([@bb0165], [@bb0025]). A 3-fold lower intrinsic clearance for cyclophosphamide was observed with recombinant *CYP2C9*\**2* and *CYP2C9*\**3* protein when compared to *CYP2C9*\**1* protein in a yeast expression system ([@bb0070]). The MDR modulator, verapamil, has been reported to be metabolized by *CYP2C9*, which may have an impact on the concomitant use of chemotherapeutic drugs and verapamil ([@bb0035]). *CYP2C9* enzyme has been shown to play a key role in the metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) that are frequently used in cancer patients suggesting that the doses of NSAIDs, should be carefully individualized in these patients ([@bb0065]).

In addition, *CYP2C9* enzyme also metabolizes several carcinogenic and mutagenic substrates including heterocyclic aromatic amines and polycyclic aromatic hydrocarbons, PAHs ([@bb0260], [@bb0250]). It has also been shown that some of the reactions catalyzed by *CYP2C9* lead to detoxification of carcinogens ([@bb0020], [@bb0040]). Genetic polymorphism has also been reported for *CYP2C9*. *CYP2C9*\**2* and *CYP2C9*\**3* genotypes account for "poor metabolizer" (PM) phenotype resulting in the slow metabolism of drugs and other substrates metabolized by *CYP2C9* ([@bb0130], [@bb0095]). Significant differences are known to exist in the distribution of the variant alleles of *CYP2C9* in different population. In general, the polymorphism in *CYP2C9* is more frequent in Caucasians when compared to Orientals (Chinese & Japanese population) ([@bb0220], [@bb0205], [@bb0135]). An increased frequency of *CYP2C9*\**2* allele in the patients with lung cancer has been reported ([@bb0125]). Variant alleles of *CYP2C9* were reported to increase the risk of distal colorectal adenoma ([@bb0040], [@bb0210]).

Previous study from our laboratory has shown that PMs of *CYP2C19* are involved in modulating the susceptibility to HNSCC and exhibit poor response to chemotherapy ([@bb0230]). The present study, therefore, now attempted to investigate the association of *CYP2C9* genotypes which leads to poor metabolizer (PM) status with HNSCC risk and outcome of treatment in the patients receiving chemotherapy and combination of radio-chemotherapy. Attempts were also made to investigate the interaction of *CYP2C9*\**2* & *CYP2C19*\**3* genotypes with tobacco and alcohol in modifying the HNSCC risk.

2. Materials and methods {#s0010}
========================

2.1. Study subjects {#s0015}
-------------------

A case--control study was conducted at King George\'s Medical University (KGMU), Lucknow, India. 750 males suffering from HNSCC and visiting the OPD facility of Radiotherapy Department of KGMU and equal number of controls were included in the study. The cases had squamous cell carcinoma of the oral cavity or pharynx or larynx which was confirmed by cytological, imaging and histopathological examinations and were advised a combination treatment of chemo- and radiotherapy. All the subjects included in the study belonged to the same ethnic group (Indo-European community) of North India. Controls were frequency-matched to cases by year of birth in 5-year classes. Based on medical check-up, controls were not found to suffer from any chronic disease.

The protocol of the study was approved by the human ethics committee of Chhatrapati Shahuji Maharaj Medical University, Lucknow, where the patients were registered and it conforms to the provisions of the declaration of Helsinki. Informed consent was obtained from the study subjects for inclusion in the study and before the collection of blood samples and it was also ensured that the subject anonymity was maintained. All study subjects completed a questionnaire covering medical, residential and occupational history. Information pertaining to dietary habits, family history of disease, smoking, tobacco chewing and alcohol drinking was also included in the questionnaire filled by the subjects. Subjects having regular smoking habits and smoking index (cigarettes/day × 365 days) of 730 or more were classified as smokers ([@bb0150]). Likewise, smokeless tobacco dose was estimated as 'chewing year' (i.e. CY = frequency of tobacco chewed or kept/day × duration of year). Those who had CY of 365 or more were considered as tobacco chewers ([@bb0185]). Similarly, cumulative exposure to alcohol drinking was derived by multiplying the total yearly consumption of alcohol (in L/year) by the duration of habitual alcohol drinking (in years). Those who had cumulative exposure to alcohol about 90 L were considered as regular alcohol users in our study ([@bb0100]).

2.2. DNA isolation and CYP2C9 genotyping {#s0020}
----------------------------------------

500 μL blood samples collected in citrate containing tubes from the study subjects were processed for the isolation of genomic DNA whole blood using QIAamp DNA mini kit (Qiagen, CA) following the manufacturers\' protocol. For identifying the polymorphism in *CYP2C9* (*CYP2C9*\**2* and *CYP2C9*\**3*), the reaction mixture in 50 μL contained 1 × buffer (10 mM Tris--Hcl pH 8.3, 1.5--3.0 mM of MgCl~2~, 25 mM KCl), 200 mM of each nucleotide, 200 nM of each of *CYP2C9*\**2* or 2C9\*3 primers ([@bb0220]), 1.5 unit of Taq polymerase (MBI Fermentas, Germany), 100 ng of genomic DNA and sterile milliQ water and was processed for PCR. Amplified PCR products were digested with AvaII or NsiI (MBI Fermentas, Germany) for identifying *CYP2C9*\**2* and *CYP2C9*\**3* respectively ([@bb0220]). The products were resolved by 3% agarose gel containing ethidium bromide as described earlier ([@bb0220]).

For quality control, randomly 10% of the samples were selected and re-genotyped to confirm the authenticity of the results obtained earlier and they were found to be in 100% concordance.

2.3. Statistical analysis {#s0025}
-------------------------

We determined whether genotype or allele frequencies of *CYP2C9* polymorphism amongst the cases and controls were in Hardy--Weinberg equilibrium (HWE) using the standard chi square tests. The association between genetic polymorphisms and risk of HNSCC was estimated by calculating crude odds ratio (OR). A p-value of \< 0.05 was considered statistically significant. The statistical analysis was performed with the SPSS software package (version 11.0 for Windows; SPSS Chicago, IL). The power of the present study was found to be \> 80% as analyzed by power genetic association analysis software (<http://dceg.cancer.gov/bb/tools/pga>) at the level of significance α = 0.05 with sample size of 750 in HNSCC and 750 in controls.

2.4. Treatment and treatment response {#s0030}
-------------------------------------

Patients were subjected to 3 cycles of neo-adjuvant chemotherapy (NACT), before radiotherapy or concurrent chemotherapy with radiotherapy (CT--RT). Each cycle of NACT consisted of cisplatin (50 mg/day) from days 1 to 3 and 5-fluorouracil (1 g/day) from days 1 to 3. Each cycle was administered once in 3 weeks. CT--RT included administration of 50 mg of cisplatin once every week for 7 weeks along with 70 Gy of radiation (which could be 200 cGy or 2 Gy/fraction depending on tumor size), daily for 7 weeks.

For assessing the treatment response, patients are asked to return for follow-up for five years. During follow-up, monitoring of the patients is done by thorough serial inspection of the head and neck region --- looking for disease recurrence as well as second primary tumors. On the basis of WHO criteria the treatment outcome is divided into the following three categories:i.Complete response (CR): No detectable tumorii.Partial response (PR): More than or equal to 75% decrease in tumor in its largest dimensioniii.No response (NR): Less than or equal to 50% decrease in tumor in its largest dimension

Those exhibiting CR & PR are categorized as responders while patients exhibiting NR are classified as non-responders ([@bb0230]).

3. Results {#s0035}
==========

The distribution of demographic variables and putative risk factors of HNSCC are summarized in [Table 1](#t0005){ref-type="table"}. In general, cigarette smoking, tobacco chewing and daily alcohol use were found to be prevalent in the patients when compared to the controls ([Table 1](#t0005){ref-type="table"}). [Table 2](#t0010){ref-type="table"} summarizes the genotypic frequencies of *CYP2C9*\**2* & *CYP2C9*\**3* in the controls and cases respectively. The distribution of CYP2C9\*2 (chi square: 34.93 at 1 d.f.) and CYP2C9\*3 (chi square: 32.49 at 1 d.f.) genotypes in the controls showed deviation from Hardy--Weinberg equilibrium (HWE) while that of CYP2C19\*2 (chi square: 3.22 at 1 d.f.) was in HWE, though at a borderline significance. The frequency of heterozygous genotypes (CT) of *CYP2C9*\**2* polymorphism was found to be higher in the cases (26.6%) when compared to the controls (14%). This increase in frequency resulted in an increased OR (2.22; 95% CI 1.51--3.26) in cases which was found to be statistically significant. Likewise, the frequency of homozygous genotype (TT) was slightly higher in cases (7.7%) when compared to the controls (4.6%) that resulted in an increase in risk (OR: 1.75) which, however, was not found to be statistically significant. Adjustment of the data for age, cigarette smoking, and tobacco chewing and alcohol consumption revealed that the risk continued to be significantly increased (Adj. OR: 2.72; 95% CI: 1.78--4.14) in the cases with heterozygous genotype (CT) of *CYP2C9*\**2* polymorphism ([Table 2](#t0010){ref-type="table"}). Likewise, the frequency of heterozygous and homozygous mutant genotypes *CYP2C9*\**3* was found to be increased in the cases when compared to the controls that increased the HNSCC risk which was statistically significant. Adjustment of the data for age, cigarette smoking, tobacco chewing and alcohol consumption revealed that the risk continued to be significantly increased in the cases with heterozygous genotype (AC) of *CYP2C9*\**3* polymorphism ([Table 2](#t0010){ref-type="table"}).

As with *CYP2C9*\**2* polymorphism, an increase in the frequency of heterozygous genotype (45.4%) of *CYP2C19*\**2* was observed in cases when compared to the controls (34.3%). The increase in frequency was associated with an increase in the OR (1.60; 95% CI 1.17--2.16) which was found to be statistically significant. An increase in the frequency of homozygous mutant genotype (18%) was also observed in the cases when compared to the controls (8.3%) and that resulted in a statistically significant increase in OR (2.43; 95% CI 1.17--2.16) in the cases ([Table 2](#t0010){ref-type="table"}). Adjustment of the data for age, cigarette smoking, tobacco chewing and alcohol consumption revealed that the risk continued to be significantly increased in the cases for both, heterozygous (adjusted OR: 2.05; 95% CI: 1.45--2.91; p-value: 0.000) or homozygous mutant genotype (adjusted OR: 3.25; 95% CI: 1.93--5.49; p-value: 0.000) when compared to the controls ([Table 2](#t0010){ref-type="table"}).

The effect of interaction of the risk modifiers such as tobacco chewing, cigarette smoking and alcohol consumption with the *CYP2C9* genotypes in the controls and cases is summarized in [Table 3](#t0015){ref-type="table"}. The number of individuals with variant genotypes (homozygous & heterozygous) of *CYP2C9*\**2* was significantly increased in cases (38.5%), who were regular tobacco chewers as compared to the controls (12.5%) with similar habit of tobacco chewing. The increase in the frequency resulted in several fold statistically significant increase in the OR (4.3; 95% CI: 2.2--8.6) amongst the tobacco chewing cases. As observed with *CYP2C9*\**2*, the frequency of individuals who were regular tobacco chewers with variant genotypes of *CYP2C9*\**3* was also increased significantly in cases (35.6%) when compared to the controls (14.6%). The increase in the frequency resulted in 3--4 fold statistically significant increase in the risk (OR: 3.2, 95% CI: 1.7--6.1) ([Table 3](#t0015){ref-type="table"}).

Cigarette smoking also increased the risk to HNSCC in the cases with *CYP2C9* polymorphism when compared to the smokers in the controls ([Table 3](#t0015){ref-type="table"}). The frequency of individuals who were regular smokers and carried variant genotypes of *CYP2C9*\**2* (40.9%) was significantly increased in the cases as compared to the controls (13.7%). The OR associated with cigarette smoking increased several fold in the patients with the variant genotypes of *CYP2C9*\**2* (4.4; 95% CI: 2.3--8.4) which was found to be statistically significant (p-value: 0.000). As observed with *CYP2C9*\**2* variants, the number of cases with variant genotypes of *CYP2C9*\**3* was also increased amongst smokers (30.3%) as compared to the controls (14.7%). Further, this increase was associated with an increased risk (OR: 2.5, 95% CI: 1.3--4.8), which was found to be statistically significant ([Table 3](#t0015){ref-type="table"}).

Our data further showed that frequency of the individuals with variant genotypes of *CYP2C9*\**2* and who were regular alcohol users significantly increased in the cases (57%) when compared to the controls (16.9%). This increase in frequency was associated with almost 4-fold increase in the risk (OR: 3.7, 95% CI: 2.0--7.0) to HNSCC in the cases ([Table 3](#t0015){ref-type="table"}). As observed with *CYP2C9*\**2* variants, the number of cases with variant (homozygous & heterozygous) genotypes of *CYP2C9*\**3* also increased amongst alcohol users (28.2%) as compared to the controls (8.4%). A similar increase in risk was also observed in cases amongst the alcohol users with variant genotypes of *CYP2C9*\**3* when compared to the alcohol users in the controls. Moreover, this increase in the risk (OR: 4.3; 95% CI: 1.9--9.8) was also found to be statistically significant ([Table 3](#t0015){ref-type="table"}).

A follow-up study was also carried out in 390 patients to investigate the effect of treatment on the patients with different genotypes of *CYP2C9* ([Table 4](#t0020){ref-type="table"}). Amongst the patients with wild type genotype of *CYP2C9* (*CYP2C9*\**1*), 73% responded to the treatment of chemo- and radiotherapy (Responders) while 27% showed almost negligible response (non-responders). Amongst the patients with variant genotypes of *CYP2C9*\**2*, only 37% could be categorized as responders while 63% were found to be non-responders. Likewise, amongst the PMs with *CYP2C9*\**3* genotypes, only 34.2% responded to the treatment while 65.8% could be categorized as non-responders ([Table 4](#t0020){ref-type="table"}). Interestingly, amongst 7 cases who carried compound heterozygous genotype of *CYP2C9*\**2*/\*3 (cases with both the heterozygous i.e. *CYP2C9*\**1*/\**2* & *CYP2C9*\**1*/\**3*) of *CYP2C9*, 5 (71.4%) did not respond to the treatment while only 2 (28.6%) were found to be responders ([Table 4](#t0020){ref-type="table"}).

4. Discussion {#s0040}
=============

The data of the present study has shown that functionally important polymorphism of *CYP2C9* exists in North Indian population. The frequency of the variant genotypes of *CYP2C9* (*CYP2C9*\**1*/\**2* & *CYP2C9*\**3*) was found to be higher (14% & 3% respectively) than that reported in South Indian (7% and 1%) population ([@bb0005], [@bb0155]). This could be partly attributed to the population structure of India comprising a mixture of endogamous ethnic groups ([@bb0155]). The frequency of the *CYP2C9*\**2* genotypes in our control population was higher than that observed in other Asian population (Chinese & Japanese) but was comparable to the Caucasians ([@bb0220], [@bb0205], [@bb0135]). It was observed that the *CYP2C9*\**3* polymorphism was more common in North Indian population. The frequency of the variant genotype *CYP2C9*\**3* was relatively higher (3%) when compared to the Chinese population (0.01%) but relatively lesser than found in the Caucasians (7%) ([@bb0220], [@bb0205], [@bb0135]). As observed with other studies ([@bb0095], [@bb0115];), the distribution of CYP2C9\*2 and CYP2C9\*3 genotypes in the controls showed deviation from Hardy--Weinberg equilibrium (HWE) which may be possibly due to recent population admixture. As reported earlier ([@bb0120]), CYP2C9\*2 and CYP2C9\*3 genotypes do not exhibit linkage disequilibrium (LD) in our study.

A relatively higher prevalence of cases with variant genotypes of CYP2C9\*2 or \*3 have clearly indicated that individuals inheriting PM genotypes of CYP2C9 are at increased risk to develop HNSCC. Though the association of CYP2C9 polymorphism has not been relatively well characterized with HNSCC, an increased frequency of CYP2C9\*2 allele has been reported in the cases suffering from lung cancer ([@bb0145], [@bb0125]). Using reconstituted system, microsomes prepared from *Saccharomyces cerevisiae* expressing recombinant human CYPs, CYP2C9 was found to catalyze both activation and inactivation reactions of benzo\[a\]pyrene, B\[a\]P ([@bb0020], [@bb0175], [@bb0060]). Similarly, amongst human CYPs expressed in vaccinia virus, CYP2C9 gave the highest activity for the metabolism of BP-7,8 diol to the diol epoxides, thus identifying the role of CYP2C9 in the metabolism and activation of B\[a\]P ([@bb0020], [@bb0175], [@bb0060]). Further, higher affinity for CYP2C9 has been shown for B\[a\]P when compared to PAH-metabolizing CYPs such as CYP1A and 2E1 and B\[a\]P is reported to be mutagenically activated by CYP2C9 and 2C19 along with other CYPs ([@bb0240], [@bb0235]). It has also been shown that CYP2C9 is involved in the detoxification of PAHs derived from tobacco smoke ([@bb0195], [@bb0020], [@bb0210], [@bb0040]). Consistent with these reports, a high correlation has also been observed between total DNA adducts and CYP2C isoenzymes in larynx ([@bb0055]). Thus, the association of CYP2C9 polymorphism with HNSCC risk could be attributed to the possible involvement of CYP2C isoenzymes in the metabolic activation as well as detoxification of PAHs and other tobacco derived products ([@bb0055]).

Our study has further indicated that the risk to HNSCC was increased in cases who were tobacco or alcohol users, suggesting that interaction of *CYP2C9* genotypes with tobacco or alcohol increases the susceptibility to HNSCC. The increased risk observed in cases using tobacco with PM genotypes of *CYP2C9* could thus be explained by higher affinity of *CYP2C9* for B\[a\]P ([@bb0240]). *CYP2C9* variant alleles have also been associated with altered metabolism of alkylating agents that are well established mutagens ([@bb0045]). It has also been shown that the risk of colorectal cancer or gastric cancer was found to be increased in cases who had a history of smoking and carried PM genotypes of CYP2C9 ([@bb0200], [@bb0210]). An association has also been reported between high levels of bronchial bulky DNA adduct with CYP2C9 genotypes in lung cancer cases with increased formation of bronchial bulky DNA adduct in cases with CYP2C9\*2 alleles compared to those with CYP2C9\*3 ([@bb0145]). Likewise, an increase in risk in cases of drinking alcohol with *CYP2C9* PM genotypes has suggested that alcohol possibly interacts with *CYP2C9* genotypes in increasing the risk to HNSCC. Epidemiological studies have also reported that alcohol acts synergistically with tobacco to promote carcinogenesis in HNSCC. Though not much data is available on interaction of *CYP2C9* genotypes & alcohol, ethanol is known to inhibit *CYP2C9* activity ([@bb0080]). The increase in risk in alcohol users could be explained by delayed detoxification of tobacco derived products in cases with PM genotypes of CYP2C9.

Our study has further shown that chemotherapeutic response is modified in patients with PM genotypes of CYP2C9. The poor response rate in the patients with PM genotypes and treated with radio & chemotherapy regimen could probably be a result of decreased availability of metabolites in PMs. Pharmacogenetic studies have shown that polymorphism in genes involved in drug metabolism and transport influences interindividual variability in drug efficacy and adverse effects in cancer treatment ([@bb0165], [@bb0025], [@bb0050]). Cases carrying variant alleles of thiopurine methyltransferase (*TPMT*) or dihydropyrimidine dehydrogenase (*DPYD*) or UDP-glucuronosyltransferase 1A1 (*UGT1A1*) were found to be predisposed to the toxicity/adverse effects associated with the drugs metabolized by these enzymes ([@bb0225], [@bb0215]). It has been reported that the dose and therapeutic response for several drugs in the cases vary according to the genotypic status of *CYP2C9* ([@bb0110], [@bb0160]). CYP2C subfamily (including CYP2C9 and CYP2C19) is involved in the metabolism of commonly used anticancer drugs such as ifosfamide, cyclophosphamide, thalidomide and could have an impact on the efficacy & toxicity of chemotherapeutic agents & other drugs used in standard oncology ([@bb0045], [@bb0010]). In vitro studies have demonstrated that wild type CYP2C9 was more efficient than the mutant allele CYP2C9\*3 in cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation ([@bb0045]). Kinetic studies have revealed a 3-fold lower intrinsic clearance (Vmax/Km) for cyclophosphamide in a yeast expression system with recombinant CYP2C9\*2 and CYP2C9\*3 protein when compared to CYP2C9\*1 protein ([@bb0070]). A recent study from our laboratory has also shown the involvement of PMs of *CYP2C19* in modulating the chemotherapeutic outcome in HNSCC cases ([@bb0230]).

In conclusion, the results of the present study have demonstrated that *CYP2C9* variants modulate the susceptibility to HNSCC. A several fold increase in the risk to HNSCC in the cases with variant genotypes (PMs) of *CYP2C9* and who were tobacco or alcohol users have indicated that *CYP2C9* genotypes interact with environmental risk factors in modifying the susceptibility to HNSCC. Furthermore, it was also demonstrated that PMs of *CYP2C9* modify the treatment outcome in cases receiving chemotherapy or a combination of radio- and chemotherapy.
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###### 

Distribution of demographic variables and putative risk factors of HNSCC cases.

  Characteristics       Controls n (%)   Cases n (%)
  --------------------- ---------------- -------------
  Subjects              750              750
  Age (mean ± S.D.)     50 ± 11          57 ± 9.2
  Non-tobacco chewers   545 (72.6)       475 (63.3)
   Smokers              164 (30)         394 (83.0)
   Alcohol users        55 (10.0)        109 (23.0)
  Tobacco chewers       205 (27.4)       275 (36.7)
  Non-smokers           547 (72.9)       326 (43.4)
   Tobacco chewers      170 (31)         251 (77.0)
   Alcohol users        71 (13.0)        75 (23.0)
  Smokers               203 (27.1)       424 (56.6)
  Non-alcohol users     643 (85.7)       550 (73.3)
   Tobacco chewers      129 (20.0)       259 (47.0)
   Smokers              116 (18.0)       281 (51.0)
  Alcohol users         107 (14.3)       200 (26.7)

###### 

Distribution of CYP2C9\*2 & CYP2C9\*3 genotypes amongst HNSCC cases and healthy controls.

  ------------------------------------------------------------------------------------------------------------
  Genotype frequency   Control\      Patients\     Crude OR\          p-Value    Adjusted OR^a^\    p-value
                       n = 750 (%)   n = 750 (%)   (95% CI)                      (95% CI)           
  -------------------- ------------- ------------- ------------------ ---------- ------------------ ----------
  *CYP2C9*\**2*                                                                                     

  CC                   611 (81.4)    493 (65.7)    1 (ref.)                      1 (ref.)           

  CT                   105 (14)      200 (26.6)    2.36 (2.8--3.1)    **0.00**   2.5 (1.88--3.32)   **0.00**

  TT                   34 (4.6)      57 (7.7)      2.1 (1.33--3.22)   **0.00**   2.3 (1.4--3.75)    **0.00**

                                                                                                    

  *CYP2C9*\**3*                                                                                     

  AA                   638 (85)      540 (72)      1 (ref.)                      1 (ref.)           

  AC                   90 (12)       173 (23)      2.27 (1.72--3.0)   **0.00**   2.6 (1.92--3.52)   **0.00**

  CC                   22 (3)        37 (5)        1.98 (1.15--3.4)   **0.01**   2.3 (1.3--4.1)     **0.00**
  ------------------------------------------------------------------------------------------------------------

OR: Odds ratio; CI: confidence interval; ref.: reference category, Adjusted OR^a^: adjusted in multivariate logistic regression models including age, smoking status, daily consumption of alcohol, tobacco chewing. Values in bold are statistically significant at the 0.05 levels.

###### 

Interaction between CYP2C9 genotypes and tobacco chewing, smoking and alcohol consumption and risk to HNSCC.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Tobacco chewers   Non-tobacco chewers                                                                                              
  ----------------- --------------------- ------------- ------------------ ---------- ------------- ------------- ------------------ ----------
  *CYP2C9*\**2*                                                                                                                      

  Wild type         180 (87.9)            169 (61.5)    1 (ref.)                      431 (79.1)    324 (68.2)    1 (ref.)           

  Variant           25 (12.1)             106 (38.5)    4.5 (2.78--7.32)   **0.00**   114 (20.9)    151 (30.8)    1.76 (1.3--2.3)    **0.00**

                                                                                                                                     

  *CYP2C9*\**3*                                                                                                                      

  Wild type         179 (87.2)            177 (64.4)    1 (ref.)                      459 (84.3)    363 (80.1)    1 (ref.)           

  Variant           26 (12.8)             98 (35.6)     3.8 (2.35--6.2)    **0.00**   86 (15.7)     112 (23.5)    1.65 (1.2--2.25)   **0.00**

                                                                                                                                     

  Smokers           Non-smokers                                                                                                      

                                                                                                                                     

  Genotypes         Controls\             Cases\        OR\                p-Value    Controls\     Cases\        OR\                p-Value
                    n = 203 (%)           n = 424 (%)   (95%CI)                       n = 547 (%)   n = 326 (%)   (95% CI)           

                                                                                                                                     

  *CYP2C9*\**2*                                                                                                                      

  Wild type         176 (86.5)            261 (61.5)    1 (ref.)                      435 (79.6)    232 (71.3)    1 (ref.)           

  Variant           27 (13.5)             163 (38.5)    4.0 (2.6--6.4)     **0.00**   112 (20.4)    94 (28.7)     1.6 (1.14--2.2)    **0.00**

                                                                                                                                     

  *CYP2C9*\**3*                                                                                                                      

  Wild type         175 (86)              293 (69)      1 (ref.)                      463 (84.7)    247 (75.7)    1 (ref.)           

  Variant           28 (14)               131 (31)      2.8 (1.78--4.4)    **0.00**   84 (15.3)     79 (24.3)     1.8 (1.2--2.5)     **0.00**

                                                                                                                                     

  Alcohol users     Non-alcohol                                                                                                      

                                                                                                                                     

  Genotypes         Controls\             Cases\        OR\                p-Value    Controls\     Cases\        OR\                p-Value
                    n = 107 (%)           n = 200 (%)   (95% CI)                      n = 267 (%)   n = 148 (%)   (95% CI)           

                                                                                                                                     

  *CYP2C9*\**2*                                                                                                                      

  Wild type         91 (85)               114 (57.0)    1 (ref.)                      520 (80.9)    379 (68.9)    1 (ref.)           

  Variant           16 (15)               86 (43.0)     4.3 (2.35--7.8)    **0.00**   123 (19.1)    171 (31.1)    1.9 (1.46--2.2)    **0.00**

                                                                                                                                     

  *CYP2C9*\**3*                                                                                                                      

  Wild type         95 (88.9)             144 (71.8)    1 (ref.)                      543 (84.5)    396 (72)      1 (ref.)           

  Variant           12 (11.1)             56 (28.2)     3.1 (1.5--6.04)    **0.00**   100 (15.5)    154 (28)      2.1 (1.6--2.8)     **0.00**
  ---------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio; CI: confidence interval; ref.: reference category; variant --- heterozygous and homozygous mutant genotype. Values in bold are statistically significant at the 0.05 levels.

###### 

Treatment responses in patients of HNSCC with CYP2C9 genotypes.

  ---------------------------------------------------------------------------------
  Genotypes                Cases\        Responders\   Non-responders\   p-Value
                           n = 390 (%)   (%)           (%)               
  ------------------------ ------------- ------------- ----------------- ----------
  *CYP2C9*\**1*            148 (37.8)    108 (73.0)    40 (27.0)         Ref

  *CYP2C9*\**2*            142 (36.5)    54 (38.0)     88 (62.0)         0.0000\*

  *CYP2C9*\**3*            0.0000\*      36 (35.6)     64 (64.4)         0.0000\*

  *VarCYP2C9*\**2*/\**3*   96 (24.7)     36 (37.7)     60 (62.3)         0.0000\*

  *HomCYP2C9*\**2*/\**3*   12 (3.0)      3 (25.0)      9 (75.0)          0.0000\*
  ---------------------------------------------------------------------------------

Responder: Based on 50% reduction in tumor size, clinical response 50% & above by imaging, CTMRI, endoscopy techniques & symptomology (based on WHO criteria).

Non-responder: Less than 50% clinical response.

*Var*: Cases carrying both homozygous and heterozygous variants of both CYP2C9\*2 & CYP2C9\*3. \*p \< 0.05 is considered statistically significant.

*Hom*: Cases carrying only homozygous variants of both CYP2C9\*2 & CYP2C9\*3.

[^1]: Present address: Amity Institute of Biotechnology, Amity University, Sector 125, Noida 201303, UP, India.

[^2]: Contributed equally to the manuscript.

[^3]: Present address: Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Science, Raebareli Road, Lucknow-226014, U.P, India.
